Tirzepatide 3 Month Results: Clinical Data and Patient Outcomes

Three months on tirzepatide is when treatment momentum truly builds. By 12 weeks, most patients have titrated from the 2.5 mg starting dose to 5-7.5 mg, and the dual GIP/GLP-1 mechanism is producing meaningful, consistent weight loss. SURMOUNT trial data shows average weight loss of 7-10% of starting body weight at this timepoint.

Medical Disclaimer: This article is for informational purposes only. Individual results vary based on dose, adherence, lifestyle, and biology.

3-Month Weight Loss by Dose

Dose at 12 Weeks	Avg. % Body Weight Lost	Avg. lbs (230 lb start)
5 mg	~7-8%	~16-18 lbs
7.5 mg	~8-9%	~18-21 lbs
10 mg (fast titration)	~9-10%	~21-23 lbs

Month-by-Month Progression

Month	Typical Dose	Monthly Loss	Cumulative Loss
Month 1	2.5 mg	3-7 lbs	3-7 lbs
Month 2	5 mg	5-8 lbs	8-15 lbs
Month 3	5-7.5 mg	5-8 lbs	13-23 lbs

Tirzepatide vs. Semaglutide at 3 Months

Metric	Tirzepatide	Semaglutide
Avg. % body weight lost	7-10%	5-8%
Avg. lbs lost (220-230 lb start)	16-23 lbs	11-18 lbs
GI side effects	Slightly lower incidence	Slightly higher incidence

Health Changes at 3 Months

Blood sugar: Significant HbA1c improvement, especially in diabetic patients (tirzepatide shows particularly strong glucose-lowering effects).
Blood pressure: Measurable systolic reduction of 4-8 mmHg.
Cholesterol: Triglycerides typically decrease 15-20%.
Waist circumference: Average reduction of 2-4 inches.
Energy and mobility: Noticeable improvement in daily activities.
Sleep quality: Many patients report better sleep.

Frequently Asked Questions

How much weight do you lose in 3 months on tirzepatide?

Average weight loss is 7-10% of body weight depending on dose. At 5 mg (typical at 12 weeks), patients average 7-8%. With faster titration, results can reach 10%.

Is tirzepatide better than semaglutide at 3 months?

SURMOUNT data shows slightly higher average weight loss for tirzepatide at 12 weeks (7-10% vs. 5-8%). Individual responses vary, and the best medication depends on your specific situation.

What dose of tirzepatide should you be on at 3 months?

Most patients are at 5 mg or 7.5 mg by month 3, following the standard titration from 2.5 mg starting dose.

For personalized tirzepatide treatment, explore Trimi's GLP-1 programs.

Sources & References

Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.

Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.

Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.

FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

What does the published clinical evidence show for compounded tirzepatide?

Peer-reviewed evidence: Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022). Trimi offers compounded tirzepatide starting at $125/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

Key Takeaways

Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022)

In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. (Source: SURPASS-2, NEJM 2021)

Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. (Source: SURMOUNT-OSA, NEJM 2024)

Tirzepatide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Zepbound and Mounjaro). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.

Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.

Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.

This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

What real Trimi patients say

Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

— u/CSWB101Reddit (r/TirzepatideRX)

Really great customer service! Fast shipment.

Outcome: Fast shipment

— Amy KeithFacebook

Keep Reading

Tirzepatide